On Friday Feb. 19th, Nephron hosted the CEO of one of the top private solutions providers in the field, Dr. John Wilson for a discussion on the latest innovation in proteomics for mass spectrometry. Topics of discussion included the latest competitive dynamics in mass spectrometry between Bruker’s TOF Pro and Thermo Fisher’s Orbitrap, the potential for single cell proteomics, the potential for mass spectrometry to translate into the clinic, and areas of investment amidst COVID-19. Companies in focus included Bruker (BRKR), Thermo Fisher (TMO), Agilent (A), Danaher (DHR), PerkinElmer (PKI) and Waters (WAT).
